Ken Attie, MD, Vice President of Medical Research at Acceleron Pharma in Cambridge, Massachusetts, talks about the beta-thalassemia medications his company is developing with Celgene. At a meeting of the European Hematology Association, data from two clinical trials—one for each drug, ACE-011 (sotatercept) and ACE-536—showed varying improvements in red blood cell counts, reductions in transfusions, and relief of fatigue. Both medications have received the FDA’s orphan drug designation.
You are here
Promising Results for Two Beta-Thalassemia Drugs
European Hematology Association
Managed Care, and P&T are available for free on multiple mobile platforms and devices. For Apple and iOS devices, visit the Apple Store and download the free digital application for Managed Care and P&T. Search for "Managed Care," "Pharmacy and Therapeutics," or "MediMedia."